Evidence map›Paper›PMID 26725968›Full record

Trial reportMolecular oncology2016

Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.

Kjersti Tjensvoll, Morten Lapin, Tove Buhl, Satu Oltedal, Katrine Steen-Ottosen Berry, Bjørnar Gilje, Jon Arne Søreide, Millind Javle, Oddmund Nordgård, Rune Smaaland

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 4 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 4 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Kjersti TjensvollDepartment of Haematology and Oncology, Stavanger University Hospital, N-4068 Stavanger, Norway; Laboratory for Molecular Biology, Stavanger University Hospital, N-4068 Stavanger, Norway. Electronic address: ktje@sus.no.
Morten LapinLaboratory for Molecular Biology, Stavanger University Hospital, N-4068 Stavanger, Norway.
Tove BuhlDepartment of Haematology and Oncology, Stavanger University Hospital, N-4068 Stavanger, Norway.
Satu OltedalDepartment of Haematology and Oncology, Stavanger University Hospital, N-4068 Stavanger, Norway; Laboratory for Molecular Biology, Stavanger University Hospital, N-4068 Stavanger, Norway.
Katrine Steen-Ottosen BerryLaboratory for Molecular Biology, Stavanger University Hospital, N-4068 Stavanger, Norway.
Bjørnar GiljeDepartment of Haematology and Oncology, Stavanger University Hospital, N-4068 Stavanger, Norway.
Jon Arne SøreideDepartment of Gastrointestinal Surgery, Stavanger University Hospital, N-4068 Stavanger, Norway; Department of Clinical Medicine, University of Bergen, N-5021 Bergen, Norway.
Millind JavleDepartment of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oddmund NordgårdDepartment of Haematology and Oncology, Stavanger University Hospital, N-4068 Stavanger, Norway; Laboratory for Molecular Biology, Stavanger University Hospital, N-4068 Stavanger, Norway.
Rune SmaalandDepartment of Haematology and Oncology, Stavanger University Hospital, N-4068 Stavanger, Norway.
Stavanger University Hospital · NOThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

We used KRAS mutations to investigate the clinical relevance of circulating tumor DNA (ctDNA) measurements in patients with advanced pancreatic cancer. Fifty-three blood samples were collected from 14 prospectively recruited patients prior to chemotherapy (gemcitabine or FOLFIRINOX) and subsequently every month during treatment. Samples were processed by density centrifugation and plasma DNA isolation. A Peptide-nucleic acid-clamp PCR was then used to detect KRAS mutations (present in >90% of pancreatic cancers) as a surrogate marker for ctDNA. Plasma samples from 29 healthy individuals were analyzed as a reference group. Results were compared to conventional monitoring measures and survival data. Median follow-up time was 3.7 months (range 0.6-12.9 months). Ten (71%) patients had a positive KRAS status in the plasma samples obtained prior to chemotherapy, indicating the presence of ctDNA. Among the patients who were ctDNA-positive before chemotherapy, nine (90%) experienced disease progression during follow-up, compared to one (25%) of four ctDNA-negative patients (P = 0.01). The pre-therapy ctDNA level was a statistically significant predictor of both progression-free and overall survival (P = 0.014 and 0.010, respectively). Of the 14 patients, ten had ≥2 follow-up samples; in several of these patients, the ctDNA level changed substantially during the course of chemotherapy. Changes in ctDNA levels corresponded both with radiological follow-up data and CA19-9 levels for several patients. This pilot study supports the hypothesis that ctDNA may be used as a marker for monitoring treatment efficacy and disease progression in pancreatic cancer patients. Recruitment of more patients is ongoing to corroborate these findings.

Indexed as

DNA, NeoplasmPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Biomarkers, TumorDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedMutationPilot ProjectsSurvival RateBiomarkers, TumorDNA, NeoplasmKRAS protein, humanProto-Oncogene Proteins p21(ras)Cell-free DNAcfDNACirculating tumor DNActDNAKRASLiquid biopsyPancreatic cancer

Identifiers

PMID26725968
PMCPMC5423145
OpenAlexW2207038926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.